ATC Group: A05AA Bile acid preparations

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A05AA in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A05 Bile and liver therapy
3 A05A Bile therapy
4 A05AA Bile acid preparations

Group A05AA contents

Code Title
A05AA01 Chenodeoxycholic acid
A05AA02 Ursodeoxycholic acid

Active ingredients in A05AA

Active Ingredient Description
Chenodeoxycholic acid

Exogenous chenodeoxycholic acid is used as replacement therapy to restore the feedback inhibition lost due to the deficiency/absence of endogenous chenodeoxycholic acid. In CTX, deficiency of chenodeoxycholic acid causes a lack of feedback of cholesterol 7 alpha hydroxylase (CYP7A1) and HMG CoA reductase, causing increased production of atypical bile acids, bile alcohols and cholestanol that lead to the pathological consequences of the condition.

Cholic acid

Cholic acid is the predominant primary bile acid in man. In patients with inborn deficiency of 3β-Hydroxy-Δ5−C27-steroid oxidoreductase and Δ4-3-Oxosteroid-5β-reductase, the biosynthesis of primary bile acids is reduced or absent. The rational basis for treatment consists of restoration of the bile aciddependent component of bile flow enabling restoration of biliary secretion and biliary elimination of toxic metabolites; inhibition of the production of the toxic bile acid metabolites by negative feedback on cholesterol 7α-hydroxylase, which is the rate-limiting enzyme in bile acid synthesis; and improvement of the patient’s nutritional status by correcting intestinal malabsorption of fats and fat-soluble vitamins.

Obeticholic acid

Obeticholic acid is a selective and potent agonist for the farnesoid X receptor (FXR), a nuclear receptor expressed at high levels in the liver and intestine. FXR activation decreases the intracellular hepatocyte concentrations of bile acids by suppressing de novo synthesis from cholesterol, as well as, by increasing transport of bile acids out of the hepatocytes.

Ursodeoxycholic acid

The ursodeoxycholic acid converts lithogenic bile in non-lithogenic bile and gradually dissolves the cholesterol gallstones.


Related product monographs

Title Information Source Document Type  
ACTIGALL Capsule FDA, National Drug Code (US) MPI, US: SPL/Old
CHOLURSO Film-coated tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
OCALIVA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
ORPHACOL Hard capsule European Medicines Agency (EU) MPI, EU: SmPC
PROURSAN Capsule, hard Health Products Regulatory Authority (IE) MPI, EU: SmPC
URSO 250 / FORTE Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
URSOFALK Capsule, hard Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
URSOGRIX Capsule, hard Health Products Regulatory Authority (IE) MPI, EU: SmPC